{"version":"1.0","provider_name":"Leitat Technological Center","provider_url":"https:\/\/leitat.org\/es\/","author_name":"Comunicaci\u00f3n Leitat","author_url":"https:\/\/leitat.org\/es\/blog\/author\/comunica-wp\/","title":"PEGS 2015: Recombinant antibodies for research, diagnosis and therapy - Leitat Technological Center","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"J4pIT0YhXf\"><a href=\"https:\/\/leitat.org\/es\/blog\/pegs-2015-recombinant-antibodies-research-diagnosis-therapy\/\">PEGS 2015: Recombinant antibodies for research, diagnosis and therapy<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/leitat.org\/es\/blog\/pegs-2015-recombinant-antibodies-research-diagnosis-therapy\/embed\/#?secret=J4pIT0YhXf\" width=\"600\" height=\"338\" title=\"\u00abPEGS 2015: Recombinant antibodies for research, diagnosis and therapy\u00bb \u2014 Leitat Technological Center\" data-secret=\"J4pIT0YhXf\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/leitat.org\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/leitat.org\/wp-content\/uploads\/2017\/03\/PosterPSEG2015.jpg","thumbnail_width":1670,"thumbnail_height":2360,"description":"During the PEGS 2015, the Toxab project presented a poster about recombinant antibodies for research, diagnosis and therapy. Antibodies are promising candidates for basic research, diagnosis and treatment. Currently, multiple monoclonal and recombinant molecules recognizing tumor targets are in preclinical o clinical assays. Accordingly, innovative ones, biosimilars or recombinant fragments with enhanced functions are continuously [&hellip;]"}